Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $74.95 Analyst target: $107.25 Upside: 43.10%
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
See the full interactive analysis & chart →Informational only — not investment advice.